Yubo International Biotech Limited (OTCPK: YBGJ)
Health Care · Biotechnology · CN
$0.01
-45.38% today · -85.6% 1Y
Yubo International Biotech Limited (OTCPK: YBGJ) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.11M and employs 14 people.
Over the last twelve months the share price has lost 85.6%, trading between 0.01 and 0.05.
Tweenvest scores Yubo International Biotech Limited across four factors: quality 13/100, value 34/100, growth 0/100. Its strongest factor is value.
YBGJ price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.11M
- Revenue (TTM)
- $12.35K
- P/E
- —
- EPS
- -0.01
- Dividend yield
- —
- Beta (5Y)
- 0.71
- 52-week high
- $0.05
- 52-week low
- $0.01
- Avg volume (3M)
- —
- Shares outstanding
- 170.42M
- Employees
- 14
- Next earnings
- —
About Yubo International Biotech Limited
Yubo International Biotech Limited, operating through its various subsidiaries, primarily dedicates its efforts to the research, development, and practical application of endometrial stem cells. Beyond this core focus, the company also provides a diverse range of products, including solutions for respiratory health, skincare and hair care formulations, nutritious beverages, and personal care items tailored for both men and women. Furthermore, it delivers specialized stem cell services, such as cellular analysis and comprehensive health management consulting, all offered under the VIVCELL brand. The company's headquarters are located in Beijing, China.
- Listed since
- Aug 24, 2021
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.